on Theranexus (EPA:ALTHX)
THX Pharma Releases Shareholder Letter
On January 8, 2025, Lyon-based biopharmaceutical company THX Pharma, known as Theranexus, announced the publication of its letter to shareholders. The document is accessible via the company's website in the Financial Documents section. Shareholders are encouraged to register for company communications to stay informed.
Theranexus specializes in drug development for rare neurological diseases. Its lead product, TX01, is poised for commercialization across multiple markets including Europe, the US, Canada, and Australia. This drug addresses Niemann-Pick type C and Gaucher diseases. The company's second product, Batten-1, targets juvenile Batten disease, potentially becoming the first approved treatment in its class.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news